Clinical Research

Clinical Research

LVPEI has been successfully audited by United States - Food and Drug Administration Agency (US FDA) and European Medicine Agency (EMA) for performing clinical trials.

Raja Narayanan, Director, Clinical Research
Contact: 040-3061 2618
Mail: narayanan@lvpei.org


Kallam Anji Reddy Campus
Manager Operations: T. Charitha
Study Co-ordinators: Gurram Deepthi, Esankara Raju, Aseema Ghouse, Billa Soundarya, Indira Sharma
Study Optometrists: Mr. Abhilash Goud, M. Liviza
Senior Clinical Data Analyst : E. Shobha Laxmi
Data Entry Operator: Vadde Vijaya Laxmi

Contact Number: 040-3061 2123/2124

Contact Number (Bio statistician and Image Reading center): 040-3061 2170


Bhubaneswar Campus
Clinical Research Coordinator: Mr. Mohammed Hasibur Rahman, Mr. Satyajit Parida
Study Optometrists: Mr.Krushna Gopal Panda, Mr. Aniruddha Banerjee

Contact Numbers(Clinical Research): 06740 3987108


GMRV Campus
Clinical Research Coordinator: Ramya Sidagam
Study Optometrist: Karthika Maddila

Contact Numbers(Clinical Research): 07382422994

KAR Campus
S.No Title of the Project Principal Investigator Supported By Duration
1. A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trialof QPI-1007 Delivered By Single or Multi-Dose IntravitrealInjection(s) to Subjects With Acute Nonarteritic Anterior IschemicOptic Neuropathy (NAION)” (hereinafter Study),QPI-1007 (hereinafter Study Drug) Dr. Ramesha Kekunnaya PAREXEL 2016-2019
2. A Phase 3, RandomizEd, MAsked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for tHe TReatment of Subjects with Macular Edema associated with Non-Infectious UvEitis Dr. Mudit Tyagi EXCEL LIFE SCIENCES 2016-2017
3. A Prospective, Multicenter clinical study to assess safety, Immunogenicity and Efficacy of Ranibizumab (Intas Pharmaceutical Limited) for the treatment of treatment of Wet AMD(Age Related macular Degeneration) Dr. Vivek Dave LAMBDA PHARMA 2016-2018
4. A Multi-centre open-label, observational study, to evaluate the efficacy and safety of Intravitreal Injections (IVI) of Ranibizumab in patients with visual impairment due to Diabetic Macular Edema (DME) Dr. Padmaja Kumari Novartis 2016-2018
5. An observational, Multi-centre, open study assessing the efficacy and safety of Ranibizumab Intravitreal Injections in patients with visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO) Dr. Raja Narayanan Novartis 2016-2018
6. Prospective feasibility study to evaluate safety and efficacy of ultrasound ciliary plasty in refractory glaucoma patients Dr. Sirisha Senthil Eyetech 2018-2019
7. Retinopathy of Prematurity Dr. Subhadra Jalali PHFI 2016-2019
8. A Phase III, Randomized, Observer-Masked, Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution 0.002% Compared with Latanoprost Ophthalmic Solution 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension- (PEONY) Dr. Sirisha Senthil COVANCE 2017-2018
9. A randomized, Masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with Intravitreal Aflibercept in Subjects with Retinal Vein Occlusion Dr. Divya Balakrishnan EXCEL LIFE SCIENCES 2018-2019
BBSR CAMPUS
S.No Title of the Project Principal Investigator Supported By Duration
1. A Prospective, Multicenter clinical study to assess safety, Immunogenicity and Efficacy of Ranibizumab (Intas Pharmaceutical Limited) for the treatment of treatment of Wet AMD(Age Related macular Degeneration) Dr.Soumyava Basu Intas Pharmaceuticals 2016-2017
2. A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye. Dr.Soumyava Basu Psidiva Corp 2014-2018
3. A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial Of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injections To Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Dr Vivekanand Uttamrao Warkad Quark Pharmaceutical 2016-2020

GMRV CAMPUS
S.No Title of the Project Principal Investigator Supported By Duration
1. A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial Of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injections To Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Dr. Virender Sachdeva Quark Pharmaceutical 2016-2020